Broad agency announcement (BAA) award resulting from proposal TP210611
Active Definitive Contract Awarded Last action
- Contract number
- W81XWH22C0139
- Awardee
-
The Trustees Of The University Of Pennsylvania UEI GM1XX56LEP58
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,858,850
Award facts
- Opportunity
-
- W81XWH21STBIP Solicitation number
- Contract value 100% obligated
- $2,858,850.00 Current and potential, with all options
- Completion date 96% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 102 offers Basic Research
- Pricing
- Cost No Fee
- Place of performance
- Philadelphia, PA 19104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $6,399 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,852,451 |
About this award
The Defense Health Agency awarded a $2.858 million definitive contract to The Trustees Of The University Of Pennsylvania for a randomized controlled trial of sildenafil citrate to treat cerebrovascular dysfunction in chronic traumatic brain injury on September 15, 2022, with ultimate completion on December 13, 2026. The contract is priced on a cost-no-fee basis.
The originating BAA solicitation (Proposal TP210611) calls for a Phase 2b clinical trial enrolling approximately 160 chronic traumatic brain injury participants to determine the optimal phosphodiesterase-5 inhibitor dose for improving microvascular function, assess safety and tolerability across dose ranges, and measure symptom and functional outcomes over a four-week placebo-controlled, double-masked dose-finding study. The trial will include 79 participants at Walter Reed National Military Medical Center.
Place of performance is Philadelphia, PA. The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc., serves as a key subcontractor, with primary responsibility for clinical trial operations at the military medical center site. Research Triangle Institute (RTI International) serves as the data coordinating center, providing biostatistics, data management, electronic data capture system development, study protocol support, and FITBIR-compliant dataset creation across the trial's 48-month duration and two clinical sites.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | $147,440 | |
| Research Triangle Institute | $155,582 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | $146,858 | |
| Research Triangle Institute | $193,816 |
Quick answers
Who was awarded contract W81XWH22C0139?
W81XWH22C0139 was awarded to The Trustees Of The University Of Pennsylvania by Defense Health Agency (Department of Defense) on September 15, 2022.
How much is contract W81XWH22C0139 worth?
The government has obligated $2,858,850 on W81XWH22C0139.
Was contract W81XWH22C0139 competed?
The extent of competition for W81XWH22C0139 was full and open competition. The government received 102 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award